Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer

Huizhen, Liu; Sun, Lixin; Lian, Jing; Wang, Lixia; Xi, Yanfeng; Zhao, Gaoping; Wang, J.; Lan, Xiaoyu; Du, Haiyan; Yan, Wenxia; Bu, Pengcheng; Wang, Ping; Moore, Anna; Zhao, Hua

doi:10.1007/s00432-023-05020-6

Cited by 3 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, there can be discordance in PD-L1 status between primary and metastatic lesions 96, 108 . One study found an inconsistency rate of 33.0% in PD-L1 expression between primary and recurrent/metastatic lesions 109 . Another study found that the concordance of PD-L1 positivity between primary and metastatic tumors was moderate with one assay (22C3), but poor with another (SP142) 110 .…”

Section: Addressing Pd-l1 Testing Limitationsmentioning

confidence: 99%

Harnessing Immune Checkpoint Inhibitors Against Gastric Cancer: Charting the Course to Expanded Therapeutic Benefit

Chung,

Tung,

Dung

2024

Biomed. Res. Ther.

View full text Add to dashboard Cite

Cancer immunotherapy has become a groundbreaking approach in treatment, with immune checkpoint inhibitors (ICIs) showing exceptional success in blocking the pathways that tumors use to escape immune detection. This review delves into the clinical significance and predictive power of ICIs in the treatment of gastric cancer. It introduces ICIs, explaining their mechanisms of action, reviews key findings from critical trials, and discusses the role of programmed death ligand-1 (PD-L1) testing as a potential biomarker for selecting suitable patients. The review also addresses the limitations of PD-L1 testing, while highlighting emerging predictive markers and ongoing research aimed at discovering novel biomarkers, optimizing therapeutic combinations, characterizing the tumor microenvironment, and understanding mechanisms of resistance to therapy. This effort to optimize ICIs aims to extend their significant clinical benefits to a larger group of patients with gastric cancer. In summary, this review provides specialists with an updated overview of the advancements in employing immunotherapy against gastric cancer and outlines the path towards enhancing patient outcomes through continuous research and the refinement of biomarkers.

show abstract

Section: Addressing Pd-l1 Testing Limitationsmentioning

confidence: 99%